Synapse - Hematologic Malignancies, Division of

Results (13379)

Intensive therapy for NPM1 mutant AML patients: Negative impact of FLT3-ITD(high)but not FLT3-ITD(low) and FLT3TKD and role of transplant in patients over 60 years of age

Meeting Abstract

Winer, E. S.; Flamand, Y.; Shallis, R. M.; Stempel, J. M.; Goldberg, A. D.; Stahl, M. F.; Patel, A. A.; Duvall, A. S.; Abaza, Y.; Oh, T. S.; more...
Blood (2022)

Fulltext@MSK | Save

A phase 1a/b dose escalation study of the FLT3/BTK inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia

Meeting Abstract

Goldberg, A. D.; Ohanian, M.; Koller, P. B.; Cherry, M.; Altman, J. K.; Tomlinson, B.; Chandhok, N. S.; Haney, D. N.; Hu, J.; Sinha, R. K.; more...
Blood (2022)

Fulltext@MSK | Save

Clinical outcomes of patients with TP53-mutated AML after first relapse or with primary refractory disease: Results from consortium on myeloid malignancies and neoplastic diseases (COMMAND)

Meeting Abstract

Badar, T.; Atallah, E. L.; Saliba, A. N.; Shallis, R. M.; Stahl, M. F.; Bewersdorf, J. P.; Correia, G. S. D.; Patel, A. A.; Abaza, Y.; Murthy, G. S. G.; more...
Blood (2022)

Fulltext@MSK | Save

Entospletinib (ENTO) in combination with cytarabine (Ara-C) and daunorubicin (DNR) in newly diagnosed (ND) adult patients with NPM1-mutated and FLT3-ITD wild-type acute myeloid leukemia (AML) Is associated with good response and survival: A phase 2 sub-study of the beat AML master trial

Meeting Abstract

Borate, U.; Li, R.; Huang, Y.; Swords, R. T.; Traer, E.; Stein, E.; Foran, J. M.; Baer, M. R.; Duong, V. H.; Stock, W.; more...
Blood (2022)

Fulltext@MSK | Save

OGDH Is a genetic vulnerability and therapeutic target in acute myeloid leukemia

Meeting Abstract

Millman, S. E.; Chaves-Perez, A.; Morris, J. P. 4th; Chen, C. C.; Ho, Y. J.; Raman, S. J.; Yashinskie, J. J.; Mezzadra, R.; Narendra, V.; Tian, S.; more...
Blood (2022)

Fulltext@MSK | Save

Veno-occlusive disease risk and other outcomes in patients with B-cell precursor acute lymphoblastic leukemia who received inotuzumab ozogamicin and proceeded to hematopoietic stem cell transplantation: A registry-based, observational study

Meeting Abstract

De Lima, M. J. G.; Kebriaei, P.; Lanza, F.; Cho, C.; Popradi, G.; Hemmer, M. T.; Zhang, M. J.; Zhang, F.; Shah, R.; Welch, V.; more...
Blood (2022)

Fulltext@MSK | Save

Evaluation of participation and recruitment bias in a prospective real-life multicentric cohort << Real world data in lymphoma and survival in adults >> (REALYSA study) for newly diagnosed lymphoma patients over one year in a hematology department of teaching hospital

Meeting Abstract

Lan, C. L. E.; Belot, A.; Golfier, C.; Audin, B.; Sesques, P.; Bernier, A.; Safar, V.; Marquet, A.; Ferrant, E.; Lazareth, A.; more...
Blood (2022)

Fulltext@MSK | Save

A single institutional experience using romiplostim to manage treatment related thrombocytopenia in pediatric solid tumor patients

Meeting Abstract

Degliuomini, M.; Armstrong, K.; Curry, M.; Mauguen, A.; Modak, S.; Dunkel, I.; Mones, J.; Ortiz, M.
Blood (2022)

Fulltext@MSK | Save

Chronic inflammation drives p53 mutant clonal hematopoiesis via activating the NLRP1 inflammasome

Meeting Abstract

Barajas, S. O.; Vemula, S.; Chen, S.; Chen, H.; Cai, W.; Xiao, S.; Halene, S.; Abdel-Wahab, O.; Mayo, L.; Savage, S. A.; more...
Blood (2022)

Fulltext@MSK | Save

Health care resource utilization and costs of CAR T therapy in patients with large B-cell lymphoma: A retrospective US claims database analysis

Meeting Abstract

Davies, K. R.; Kamalakar, R.; Yu, J.; Huang, Y.; Wang, A.; Sail, K.; Doerr, T.; Sharmokh, S.; Mutebi, A.; Salles, G.
Blood (2022)

Fulltext@MSK | Save